A Twenty-years' Experience in Pituitary Disease.

NCT06973824 | Recruiting

• 1 other identifier: 6546
• Study Type: observational
• Target: 1,600
• Locations: 1 country
• Sites: 1

Brief Summary

Pituitary tumors represent a heterogeneous group of neoplasms by histotype. The pituitary adenomas are the most frequent heteroformation, among those affecting the pituitary gland, followed by meningiomas, craniopharyngiomas, germosomes and tumours secondary, such as metastases and lymphomas. Since these conditions are considered rare, the data epidemiology and prognosis to predict the natural history of these diseases can not be considered conclusive. Pituitary adenomas are a useful model for epidemiology in the study of pathology pituitary. Over the past 20 years, several attempts have been made to identify unique prognostic factors, which predict the outcome of these pathologies, but without To arrive at a definitive classification. The purpose of this study aims to collect clinical, biochemical, morphological and pathological data on the retrospective and prospective cohort of over 1600 patients undergoing neurosurgical removal of pituitary tumors in the last 20 years, to develop a prognostic classification.

Conditions

Pituitary Adenoma; Pituitary Cancer; Pituitary Disease

Outcome Measures

Primary Outcomes (1)

• Tumor recurrence

  Frequency of tumor recurrence at 24 months of follow-up

  From enrollement to last observation at 24 months of follow-up

Study Arms (1)

Patients with pituitary tumors

Patients with pituitary tumors, underwent surgical resection

Other: Frequency of disease recurrence

Interventions

Frequency of disease recurrence OTHER

To collect data of pituitary disease recurrence

Patients with pituitary tumors

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients older then 18 years with diagnosis of pituitary tumors (pituitary adenoma, pituitary neuroendocrine tumors, meningiomas, craniopharingiomas, germinoma, metastasis)

You may qualify if:

• Patients underwent surgery for pituitary tumors;
• pathology diagnosis of pituitary tumors;
• patients older then 18 years at diagnosis of pituitary tumors;
• years follow-up;

You may not qualify if:

• age lower then 18 years
• follow-up shorter than 2 years

Sponsors & Collaborators

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS: lead

Study Sites (1)

Fondazione Policlinico Gemelli IRCCS

Rome, IT, 00168, Italy

RECRUITING

MeSH Terms

Conditions

Pituitary Neoplasms; Pituitary Diseases

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Hypothalamic Neoplasms; Supratentorial Neoplasms; Brain Neoplasms; Central Nervous System Neoplasms; Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Hypothalamic Diseases; Endocrine System Diseases

Study Officials

• Francesco Doglietto, Prof

  Fondazione Policlinico Universitario A. Gemelli, IRCCS

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Francesco Doglietto, Prof

CONTACT

+390630155701; francesco.doglietto@policlinicogemelli.it

Sabrina Chiloiro, MD

CONTACT

sabrina.chiloiro@policlinicogemelli.it

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: January 22, 2025
• First Posted: May 15, 2025
• Study Start: March 10, 2025
• Primary Completion (Estimated): February 15, 2028
• Study Completion (Estimated): April 30, 2028
• Last Updated: May 15, 2025

Record last verified: 2025-05

Locations

IT (1)